4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, NC
Reports Third Quarter Financial Results
Reports Second Quarter Financial Results
News, Material Contracts
Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
Shareholder votes
Reports First Quarter Financial Results
Annual Report to Security Holders
Announces Fourth Quarter and Full Year 2024 Financial Results
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
Correspondence
Submission Upload
SEC Staff Correspondence
S-1MEF